Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 86

1.

Correction to: Role of the DNA damage response in prostate cancer formation, progression and treatment.

Zhang W, van Gent DC, Incrocci L, van Weerden WM, Nonnekens J.

Prostate Cancer Prostatic Dis. 2019 Jul 17. doi: 10.1038/s41391-019-0162-1. [Epub ahead of print]

PMID:
31316184
2.

HSF2BP Interacts with a Conserved Domain of BRCA2 and Is Required for Mouse Spermatogenesis.

Brandsma I, Sato K, van Rossum-Fikkert SE, van Vliet N, Sleddens E, Reuter M, Odijk H, van den Tempel N, Dekkers DHW, Bezstarosti K, Demmers JAA, Maas A, Lebbink J, Wyman C, Essers J, van Gent DC, Baarends WM, Knipscheer P, Kanaar R, Zelensky AN.

Cell Rep. 2019 Jun 25;27(13):3790-3798.e7. doi: 10.1016/j.celrep.2019.05.096.

3.

Role of the DNA damage response in prostate cancer formation, progression and treatment.

Zhang W, van Gent DC, Incrocci L, van Weerden WM, Nonnekens J.

Prostate Cancer Prostatic Dis. 2019 Jun 13. doi: 10.1038/s41391-019-0153-2. [Epub ahead of print] Erratum in: Prostate Cancer Prostatic Dis. 2019 Jul 17;:.

PMID:
31197228
4.

Correction: Functional Ex Vivo Assay Reveals Homologous Recombination Deficiency in Breast Cancer Beyond BRCA Gene Defects.

Meijer TG, Verkaik NS, Sieuwerts AM, van Riet J, Naipal KAT, van Deurzen CHM, den Bakker MA, Sleddens HFBM, Dubbink HJ, den Toom TD, Dinjens WNM, Lips E, Nederlof PM, Smid M, van de Werken HJG, Kanaar R, Martens JWM, Jager A, van Gent DC.

Clin Cancer Res. 2019 May 1;25(9):2935. doi: 10.1158/1078-0432.CCR-19-0936. No abstract available.

PMID:
31043383
5.

Ex vivo assays to predict enhanced chemosensitization by hyperthermia in urothelial cancer of the bladder.

van den Tempel N, Naipal KAT, Raams A, van Gent DC, Franckena M, Boormans JL, Kanaar R.

PLoS One. 2018 Dec 14;13(12):e0209101. doi: 10.1371/journal.pone.0209101. eCollection 2018.

6.

Ex vivo treatment of prostate tumor tissue recapitulates in vivo therapy response.

Zhang W, van Weerden WM, de Ridder CMA, Erkens-Schulze S, Schönfeld E, Meijer TG, Kanaar R, van Gent DC, Nonnekens J.

Prostate. 2019 Mar;79(4):390-402. doi: 10.1002/pros.23745. Epub 2018 Dec 5.

7.

Protocol for the STRONG trial: stereotactic body radiation therapy following chemotherapy for unresectable perihilar cholangiocarcinoma, a phase I feasibility study.

Koedijk MS, Heijmen BJM, Groot Koerkamp B, Eskens FALM, Sprengers D, Poley JW, van Gent DC, van der Laan LJW, van der Holt B, Willemssen FEJA, Méndez Romero A.

BMJ Open. 2018 Oct 15;8(10):e020731. doi: 10.1136/bmjopen-2017-020731.

8.

Functional Ex Vivo Assay Reveals Homologous Recombination Deficiency in Breast Cancer Beyond BRCA Gene Defects.

Meijer TG, Verkaik NS, Sieuwerts AM, van Riet J, Naipal KAT, van Deurzen CHM, den Bakker MA, Sleddens HFBM, Dubbink HJ, den Toom TD, Dinjens WNM, Lips E, Nederlof PM, Smid M, van de Werken HJG, Kanaar R, Martens JWM, Jager A, van Gent DC.

Clin Cancer Res. 2018 Dec 15;24(24):6277-6287. doi: 10.1158/1078-0432.CCR-18-0063. Epub 2018 Aug 23. Erratum in: Clin Cancer Res. 2019 May 1;25(9):2935.

PMID:
30139880
9.

The CST Complex Mediates End Protection at Double-Strand Breaks and Promotes PARP Inhibitor Sensitivity in BRCA1-Deficient Cells.

Barazas M, Annunziato S, Pettitt SJ, de Krijger I, Ghezraoui H, Roobol SJ, Lutz C, Frankum J, Song FF, Brough R, Evers B, Gogola E, Bhin J, van de Ven M, van Gent DC, Jacobs JJL, Chapman R, Lord CJ, Jonkers J, Rottenberg S.

Cell Rep. 2018 May 15;23(7):2107-2118. doi: 10.1016/j.celrep.2018.04.046.

10.

Heat-induced BRCA2 degradation in human tumours provides rationale for hyperthermia-PARP-inhibitor combination therapies.

van den Tempel N, Odijk H, van Holthe N, Naipal K, Raams A, Eppink B, van Gent DC, Hardillo J, Verduijn GM, Drooger JC, van Rhoon GC, Smedts DHPM, van Doorn HC, Boormans JL, Jager A, Franckena M, Kanaar R.

Int J Hyperthermia. 2018 Jun;34(4):407-414. doi: 10.1080/02656736.2017.1355487. Epub 2017 Jul 31.

PMID:
28705099
11.

Ex vivo tumor culture systems for functional drug testing and therapy response prediction.

Meijer TG, Naipal KA, Jager A, van Gent DC.

Future Sci OA. 2017 Mar 27;3(2):FSO190. doi: 10.4155/fsoa-2017-0003. eCollection 2017 Jun. Review.

12.

213Bi-Labeled Prostate-Specific Membrane Antigen-Targeting Agents Induce DNA Double-Strand Breaks in Prostate Cancer Xenografts.

Nonnekens J, Chatalic KL, Molkenboer-Kuenen JD, Beerens CE, Bruchertseifer F, Morgenstern A, Veldhoven-Zweistra J, Schottelius M, Wester HJ, van Gent DC, van Weerden WM, Boerman OC, de Jong M, Heskamp S.

Cancer Biother Radiopharm. 2017 Mar;32(2):67-73. doi: 10.1089/cbr.2016.2155.

PMID:
28301262
13.

Potentiation of Peptide Receptor Radionuclide Therapy by the PARP Inhibitor Olaparib.

Nonnekens J, van Kranenburg M, Beerens CE, Suker M, Doukas M, van Eijck CH, de Jong M, van Gent DC.

Theranostics. 2016 Jul 18;6(11):1821-32. doi: 10.7150/thno.15311. eCollection 2016.

14.

BRCA1185delAG tumors may acquire therapy resistance through expression of RING-less BRCA1.

Drost R, Dhillon KK, van der Gulden H, van der Heijden I, Brandsma I, Cruz C, Chondronasiou D, Castroviejo-Bermejo M, Boon U, Schut E, van der Burg E, Wientjens E, Pieterse M, Klijn C, Klarenbeek S, Loayza-Puch F, Elkon R, van Deemter L, Rottenberg S, van de Ven M, Dekkers DH, Demmers JA, van Gent DC, Agami R, Balmaña J, Serra V, Taniguchi T, Bouwman P, Jonkers J.

J Clin Invest. 2016 Aug 1;126(8):2903-18. doi: 10.1172/JCI70196. Epub 2016 Jul 25.

15.

Exploiting DNA repair defects for novel cancer therapies.

van Gent DC, Kanaar R.

Mol Biol Cell. 2016 Jul 15;27(14):2145-8. doi: 10.1091/mbc.E15-10-0698.

16.

XLF deficiency results in reduced N-nucleotide addition during V(D)J recombination.

IJspeert H, Rozmus J, Schwarz K, Warren RL, van Zessen D, Holt RA, Pico-Knijnenburg I, Simons E, Jerchel I, Wawer A, Lorenz M, Patıroğlu T, Akar HH, Leite R, Verkaik NS, Stubbs AP, van Gent DC, van Dongen JJ, van der Burg M.

Blood. 2016 Aug 4;128(5):650-9. doi: 10.1182/blood-2016-02-701029. Epub 2016 Jun 8.

17.

Tumor slice culture system to assess drug response of primary breast cancer.

Naipal KA, Verkaik NS, Sánchez H, van Deurzen CH, den Bakker MA, Hoeijmakers JH, Kanaar R, Vreeswijk MP, Jager A, van Gent DC.

BMC Cancer. 2016 Feb 9;16:78. doi: 10.1186/s12885-016-2119-2.

18.

In Vivo Stabilization of a Gastrin-Releasing Peptide Receptor Antagonist Enhances PET Imaging and Radionuclide Therapy of Prostate Cancer in Preclinical Studies.

Chatalic KL, Konijnenberg M, Nonnekens J, de Blois E, Hoeben S, de Ridder C, Brunel L, Fehrentz JA, Martinez J, van Gent DC, Nock BA, Maina T, van Weerden WM, de Jong M.

Theranostics. 2016 Jan 1;6(1):104-17. doi: 10.7150/thno.13580. eCollection 2016.

19.

Comparison of the Therapeutic Response to Treatment with a 177Lu-Labeled Somatostatin Receptor Agonist and Antagonist in Preclinical Models.

Dalm SU, Nonnekens J, Doeswijk GN, de Blois E, van Gent DC, Konijnenberg MW, de Jong M.

J Nucl Med. 2016 Feb;57(2):260-5. doi: 10.2967/jnumed.115.167007. Epub 2015 Oct 29.

20.

Targeted inhibition of metastatic melanoma through interference with Pin1-FOXM1 signaling.

Kruiswijk F, Hasenfuss SC, Sivapatham R, Baar MP, Putavet D, Naipal KA, van den Broek NJ, Kruit W, van der Spek PJ, van Gent DC, Brenkman AB, Campisi J, Burgering BM, Hoeijmakers JH, de Keizer PL.

Oncogene. 2016 Apr 28;35(17):2166-77. doi: 10.1038/onc.2015.282. Epub 2015 Aug 17.

21.

Attenuated XPC expression is not associated with impaired DNA repair in bladder cancer.

Naipal KA, Raams A, Bruens ST, Brandsma I, Verkaik NS, Jaspers NG, Hoeijmakers JH, van Leenders GJ, Pothof J, Kanaar R, Boormans J, van Gent DC.

PLoS One. 2015 Apr 30;10(4):e0126029. doi: 10.1371/journal.pone.0126029. eCollection 2015.

22.

REV7 counteracts DNA double-strand break resection and affects PARP inhibition.

Xu G, Chapman JR, Brandsma I, Yuan J, Mistrik M, Bouwman P, Bartkova J, Gogola E, Warmerdam D, Barazas M, Jaspers JE, Watanabe K, Pieterse M, Kersbergen A, Sol W, Celie PHN, Schouten PC, van den Broek B, Salman A, Nieuwland M, de Rink I, de Ronde J, Jalink K, Boulton SJ, Chen J, van Gent DC, Bartek J, Jonkers J, Borst P, Rottenberg S.

Nature. 2015 May 28;521(7553):541-544. doi: 10.1038/nature14328. Epub 2015 Mar 23.

23.

An XRCC4 splice mutation associated with severe short stature, gonadal failure, and early-onset metabolic syndrome.

de Bruin C, Mericq V, Andrew SF, van Duyvenvoorde HA, Verkaik NS, Losekoot M, Porollo A, Garcia H, Kuang Y, Hanson D, Clayton P, van Gent DC, Wit JM, Hwa V, Dauber A.

J Clin Endocrinol Metab. 2015 May;100(5):E789-98. doi: 10.1210/jc.2015-1098. Epub 2015 Mar 5.

24.

PARP inhibitors: the journey from research hypothesis to clinical approval.

Naipal KA, van Gent DC.

Per Med. 2015 Mar;12(2):139-154. doi: 10.2217/pme.14.71.

PMID:
29754541
25.

DNA damage response and anti-apoptotic proteins predict radiosensitization efficacy of HDAC inhibitors SAHA and LBH589 in patient-derived glioblastoma cells.

Pont LM, Naipal K, Kloezeman JJ, Venkatesan S, van den Bent M, van Gent DC, Dirven CM, Kanaar R, Lamfers ML, Leenstra S.

Cancer Lett. 2015 Jan 28;356(2 Pt B):525-35. doi: 10.1016/j.canlet.2014.09.049. Epub 2014 Oct 8.

PMID:
25305451
26.

Functional ex vivo assay to select homologous recombination-deficient breast tumors for PARP inhibitor treatment.

Naipal KA, Verkaik NS, Ameziane N, van Deurzen CH, Ter Brugge P, Meijers M, Sieuwerts AM, Martens JW, O'Connor MJ, Vrieling H, Hoeijmakers JH, Jonkers J, Kanaar R, de Winter JP, Vreeswijk MP, Jager A, van Gent DC.

Clin Cancer Res. 2014 Sep 15;20(18):4816-26. doi: 10.1158/1078-0432.CCR-14-0571. Epub 2014 Jun 24.

27.

Similar recombination-activating gene (RAG) mutations result in similar immunobiological effects but in different clinical phenotypes.

IJspeert H, Driessen GJ, Moorhouse MJ, Hartwig NG, Wolska-Kusnierz B, Kalwak K, Pituch-Noworolska A, Kondratenko I, van Montfrans JM, Mejstrikova E, Lankester AC, Langerak AW, van Gent DC, Stubbs AP, van Dongen JJ, van der Burg M.

J Allergy Clin Immunol. 2014 Apr;133(4):1124-33. doi: 10.1016/j.jaci.2013.11.028. Epub 2014 Jan 11.

PMID:
24418478
28.

A regulatory role for the cohesin loader NIPBL in nonhomologous end joining during immunoglobulin class switch recombination.

Enervald E, Du L, Visnes T, Björkman A, Lindgren E, Wincent J, Borck G, Colleaux L, Cormier-Daire V, van Gent DC, Pie J, Puisac B, de Miranda NF, Kracker S, Hammarström L, de Villartay JP, Durandy A, Schoumans J, Ström L, Pan-Hammarström Q.

J Exp Med. 2013 Nov 18;210(12):2503-13. doi: 10.1084/jem.20130168. Epub 2013 Oct 21.

29.

Clinical spectrum of LIG4 deficiency is broadened with severe dysmaturity, primordial dwarfism, and neurological abnormalities.

IJspeert H, Warris A, van der Flier M, Reisli I, Keles S, Chishimba S, van Dongen JJ, van Gent DC, van der Burg M.

Hum Mutat. 2013 Dec;34(12):1611-4. doi: 10.1002/humu.22436. Epub 2013 Sep 18.

30.

From DNA damage to chromosome aberrations: joining the break.

Durante M, Bedford JS, Chen DJ, Conrad S, Cornforth MN, Natarajan AT, van Gent DC, Obe G.

Mutat Res. 2013 Aug 30;756(1-2):5-13. doi: 10.1016/j.mrgentox.2013.05.014. Epub 2013 May 23.

PMID:
23707699
31.

Essential role for DNA-PK-mediated phosphorylation of NR4A nuclear orphan receptors in DNA double-strand break repair.

Malewicz M, Kadkhodaei B, Kee N, Volakakis N, Hellman U, Viktorsson K, Leung CY, Chen B, Lewensohn R, van Gent DC, Chen DJ, Perlmann T.

Genes Dev. 2011 Oct 1;25(19):2031-40. doi: 10.1101/gad.16872411.

32.

Spatiotemporal aspects of MicroRNA-mediated gene regulation.

Pothof J, van Gent DC.

Adv Exp Med Biol. 2011;722:75-85. doi: 10.1007/978-1-4614-0332-6_5. Review.

PMID:
21915783
33.

MicroRNAs, the DNA damage response and cancer.

Wouters MD, van Gent DC, Hoeijmakers JH, Pothof J.

Mutat Res. 2011 Dec 1;717(1-2):54-66. doi: 10.1016/j.mrfmmm.2011.03.012. Epub 2011 Apr 6. Review.

PMID:
21477600
34.

Artemis splice defects cause atypical SCID and can be restored in vitro by an antisense oligonucleotide.

Ijspeert H, Lankester AC, van den Berg JM, Wiegant W, van Zelm MC, Weemaes CM, Warris A, Pan-Hammarström Q, Pastink A, van Tol MJ, van Dongen JJ, van Gent DC, van der Burg M.

Genes Immun. 2011 Sep;12(6):434-44. doi: 10.1038/gene.2011.16. Epub 2011 Mar 10.

PMID:
21390052
35.

The DNA damage repair protein Ku70 interacts with FOXO4 to coordinate a conserved cellular stress response.

Brenkman AB, van den Broek NJ, de Keizer PL, van Gent DC, Burgering BM.

FASEB J. 2010 Nov;24(11):4271-80. doi: 10.1096/fj.10-158717. Epub 2010 Jun 22.

PMID:
20570964
36.

A novel radiosensitive SCID patient with a pronounced G(2)/M sensitivity.

Wiegant WW, Meyers M, Verkaik NS, van der Burg M, Darroudi F, Romeijn R, Bernatowska E, Wolska-Kusnierz B, Mikoluc B, Jaspers NG, Vreeken C, Ijspeert H, Esveldt-van Lange RE, Friedl AA, de Villartay JP, Mullenders LH, van Dongen JJ, van Gent DC, Pastink A, Zdzienicka MZ.

DNA Repair (Amst). 2010 Apr 4;9(4):365-73. doi: 10.1016/j.dnarep.2009.12.004. Epub 2010 Jan 15.

PMID:
20079696
37.

DNA double strand break repair: zooming in on the focus.

van Gent DC, Hoeijmakers JH.

Cell Cycle. 2009 Dec;8(23):3813-5. Epub 2009 Dec 1. No abstract available.

PMID:
19887914
38.

DNA-PKcs deficiency in human: long predicted, finally found.

van der Burg M, van Dongen JJ, van Gent DC.

Curr Opin Allergy Clin Immunol. 2009 Dec;9(6):503-9. doi: 10.1097/ACI.0b013e3283327e41. Review.

PMID:
19823081
39.

MicroRNA responses and stress granule formation modulate the DNA damage response.

Pothof J, Verkaik NS, Hoeijmakers JH, van Gent DC.

Cell Cycle. 2009 Nov 1;8(21):3462-8. Epub 2009 Nov 17.

PMID:
19823042
40.

NBS1 cooperates with homologous recombination to counteract chromosome breakage during replication.

Brugmans L, Verkaik NS, Kunen M, van Drunen E, Williams BR, Petrini JH, Kanaar R, Essers J, van Gent DC.

DNA Repair (Amst). 2009 Dec 3;8(12):1363-70. doi: 10.1016/j.dnarep.2009.09.002. Epub 2009 Sep 25.

41.

MicroRNA-mediated gene silencing modulates the UV-induced DNA-damage response.

Pothof J, Verkaik NS, van IJcken W, Wiemer EA, Ta VT, van der Horst GT, Jaspers NG, van Gent DC, Hoeijmakers JH, Persengiev SP.

EMBO J. 2009 Jul 22;28(14):2090-9. doi: 10.1038/emboj.2009.156. Epub 2009 Jun 18.

42.

Reaching out for the other end with p53-binding protein 1.

van Gent DC.

Trends Biochem Sci. 2009 May;34(5):226-9. doi: 10.1016/j.tibs.2009.01.009. Epub 2009 Apr 15.

PMID:
19375329
43.

A mouse model for chronic lymphocytic leukemia based on expression of the SV40 large T antigen.

ter Brugge PJ, Ta VB, de Bruijn MJ, Keijzers G, Maas A, van Gent DC, Hendriks RW.

Blood. 2009 Jul 2;114(1):119-27. doi: 10.1182/blood-2009-01-198937. Epub 2009 Mar 30.

PMID:
19332766
44.

The Ku80 carboxy terminus stimulates joining and artemis-mediated processing of DNA ends.

Weterings E, Verkaik NS, Keijzers G, Florea BI, Wang SY, Ortega LG, Uematsu N, Chen DJ, van Gent DC.

Mol Cell Biol. 2009 Mar;29(5):1134-42. doi: 10.1128/MCB.00971-08. Epub 2008 Dec 22.

45.

A DNA-PKcs mutation in a radiosensitive T-B- SCID patient inhibits Artemis activation and nonhomologous end-joining.

van der Burg M, Ijspeert H, Verkaik NS, Turul T, Wiegant WW, Morotomi-Yano K, Mari PO, Tezcan I, Chen DJ, Zdzienicka MZ, van Dongen JJ, van Gent DC.

J Clin Invest. 2009 Jan;119(1):91-8. doi: 10.1172/JCI37141. Epub 2008 Dec 15.

46.

Non-homologous end-joining, a sticky affair.

van Gent DC, van der Burg M.

Oncogene. 2007 Dec 10;26(56):7731-40. Review.

PMID:
18066085
47.

Defective Artemis nuclease is characterized by coding joints with microhomology in long palindromic-nucleotide stretches.

van der Burg M, Verkaik NS, den Dekker AT, Barendregt BH, Pico-Knijnenburg I, Tezcan I, vanDongen JJ, van Gent DC.

Eur J Immunol. 2007 Dec;37(12):3522-8.

48.

Autophosphorylation of DNA-PKCS regulates its dynamics at DNA double-strand breaks.

Uematsu N, Weterings E, Yano K, Morotomi-Yano K, Jakob B, Taucher-Scholz G, Mari PO, van Gent DC, Chen BP, Chen DJ.

J Cell Biol. 2007 Apr 23;177(2):219-29. Epub 2007 Apr 16.

49.

DNA double-strand break repair: from mechanistic understanding to cancer treatment.

Helleday T, Lo J, van Gent DC, Engelward BP.

DNA Repair (Amst). 2007 Jul 1;6(7):923-35. Epub 2007 Mar 23. Review.

PMID:
17363343
50.

Role of Artemis in DSB repair and guarding chromosomal stability following exposure to ionizing radiation at different stages of cell cycle.

Darroudi F, Wiegant W, Meijers M, Friedl AA, van der Burg M, Fomina J, van Dongen JJ, van Gent DC, Zdzienicka MZ.

Mutat Res. 2007 Feb 3;615(1-2):111-24. Epub 2006 Dec 12.

PMID:
17169382

Supplemental Content

Loading ...
Support Center